CYRAMZA (ramucirumab)
CYRAMZA is indicated for the treatment of Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Non-Small Cell Lung Cancer; Colorectal Cancer; Hepatocellular Carcinoma.
How CYRAMZA Works
Ramucirumab functions by specifically binding to VEGFR2, which prevents the receptor from interacting with its ligands, including VEGF-A, VEGF-C, and VEGF-D. By blocking these interactions, the drug inhibits the ligand-stimulated activation of the receptor. This process suppresses the proliferation and migration of human endothelial cells. Ultimately, this mechanism inhibits angiogenesis, the formation of new blood vessels that support tumor growth.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2014-04-21
- Patent Cliff
- 2026
- Revenue
- $200M (Q4-2025)
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
CYRAMZA Approval History
What CYRAMZA Treats
5 indicationsCYRAMZA is approved for 5 conditions since its original approval in 2014. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Hepatocellular Carcinoma
CYRAMZA Target & Pathway
ProTarget
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
Pathway Context
VEGFR on blood vessels is activated by VEGF to promote angiogenesis
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
CYRAMZA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in CYRAMZA's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications CYRAMZA treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to CYRAMZA
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
115 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT04310007 | NCI-2020-01541 NCI-2020-01541, EA5191 | Ph 2 | active not recruiting | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer |
| NCT04704934 | DS8201-A-U306 2020-004559-34 | Ph 3 | active not recruiting | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) |
| NCT06203600 | NCI-2023-11064 NCI-2023-11064, S2303 | Ph 2, Ph 3 | recruiting | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial |
| NCT06448754 eVOLVE-01 | D798KC00001 2023-509482-20-00 | Ph 2 | recruiting | Volrustomig Priming Regimens Exploratory Phase II Platform Study |
| NCT06445972 | 3475-06D 2023-509306-29-00, U1111-1299-8160 | Ph 1, Ph 2 | recruiting | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) |
| NCT06043427 | GA4 | Ph 2 | recruiting | Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma |
| NCT04145349 results posted | 17305 J1S-MC-JV01, 2018-004242-42 | Ph 1, Ph 2 | completed | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor |
| NCT05642572 | S1900G NCI-2022-09254, S1900G | Ph 2 | recruiting | Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) |
| NCT05365581 | 2138-CL-0101 jRCT2031210644, CTR20241945 | Ph 1 | recruiting | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer |
| NCT06616584 | S1800E NCI-2024-06444, S1800E | Ph 2, Ph 3 | recruiting | Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) |
| NCT06031688 | S1900K NCI-2023-04727, S1900K | Ph 2 | recruiting | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) |
| NCT03650764 | 201809094 | Ph 1, Ph 2 | completed | Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
| NCT06996782 ALTAIR | D702KC00001 2024-519786-22 | Ph 1, Ph 2 | recruiting | A Platform Study in Non-Small Cell Lung Cancer (NSCLC) |
| NCT07098338 LIBRA | D6187C00001 | Ph 2 | recruiting | A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) |
| NCT07546812 | GS-US-742-7757 2025-524095-27 | Ph 2 | recruiting | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas |
| NCT03909334 | HCRN LUN18-335 | Ph 2 | active not recruiting | Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
| NCT05633602 | S2302 NCI-2022-09319, S2302 | Ph 3 | active not recruiting | Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study |
| NCT03081143 RAMIRIS | RAMIRIS AIO-STO-0415 | Ph 2, Ph 3 | active not recruiting | Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy |
| NCT06007937 | 23-131 | Ph 1, Ph 2 | recruiting | A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer |
| NCT03798626 | CVPM087A2101 2018-003952-19 | Ph 1 | completed | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers |
| NCT05980000 Rambro2 | 202308161 | Ph 2 | active not recruiting | Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma |
| NCT05999994 CAMPFIRE | 17304 J1S-MC-JAAA | Ph 2 | recruiting | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer |
| NCT04921904 | 020-055 | Ph 1, Ph 2 | active not recruiting | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca |
| NCT06771622 | HCB101-201 | Ph 1, Ph 2 | active not recruiting | Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors |
| NCT03008278 results posted | NCI-2016-02049 NCI-2016-02049, 2000021407 | Ph 1, Ph 2 | completed | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery |
| NCT04340882 DoceRamPem | STUDY00000030 NCI-2020-01134, WINSHIP4950-20 | Ph 2 | active not recruiting | Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade |
| NCT02411448 RELAY results posted | 15540 I4T-MC-JVCY, 2014-004824-22 | Ph 3 | active not recruiting | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) |
| NCT03527108 | TH-189 TH-189 | Ph 2 | active not recruiting | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC |
| NCT04332367 | UPCC 05519 IRB833759 | Ph 2 | recruiting | Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance |
| NCT03281369 | YO39609 2016-004529-17 | Ph 1, Ph 2 | completed | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) |
| NCT06251973 | 23-361 | Ph 2 | active not recruiting | A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer |
| NCT06675136 | 24445 NCI-2024-08883, 24445 | Ph 1 | recruiting | Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases |
| NCT04205968 | S1922 NCI-2019-04213, S1922 | Ph 2 | recruiting | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers |
| NCT03694002 results posted | S1701 NCI-2017-02254, S1701 | Ph 2 | completed | Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery |
| NCT02597036 results posted | 15580 I7W-MC-JQBA, 2015-001204-64 | Ph 1 | terminated | A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors |
| NCT05002127 | AT148006 | Ph 2, Ph 3 | active not recruiting | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) |
| NCT06038578 | 950GCV01 | Ph 2 | recruiting | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer |
| NCT02711553 results posted | 16329 I3O-MC-JSBF, 2015-004699-31 | Ph 2 | active not recruiting | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer |
| NCT03872947 | 950P1V02 | Ph 1 | active not recruiting | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors |
| NCT04069273 SEQUEL | HCRN GI18-333 | Ph 2 | recruiting | Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma |
| NCT04120454 results posted | OSU-19132 NCI-2019-05348 | Ph 2 | completed | Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer |
| NCT02678182 PLATFORM | 3804 | Ph 2 | active not recruiting | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial |
| NCT04394624 CARMEN-LC04 results posted | ACT16525 U1111-1244-1585, 2019-003914-15 | Ph 2 | terminated | Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) |
| NCT05096663 | S1800D NCI-2021-09852, S1800D | Ph 2, Ph 3 | active not recruiting | Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) |
| NCT03560973 RAMES | GOIRC-03-2016 | Ph 2 | completed | A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM |
| NCT05062980 Acclaim-2 | ONC-004 | Ph 1, Ph 2 | terminated | Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer |
| NCT02795858 results posted | 16-072 | Ph 2 | completed | A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors |
| NCT04499924 MOUNTAINEER-02 results posted | SGNTUC-022 C4251004 | Ph 2, Ph 3 | completed | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer |
| NCT02581215 results posted | HCRN GI14-198 | Ph 2 | completed | Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer |
| NCT02791334 PACT | 16088 I8J-MC-JYCA, 2016-000440-33 | Ph 1 | completed | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors |
Showing 50 of 115 trials
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CYRAMZA FDA Label Details
Indications & Usage
FDA Label (PDF)CYRAMZA is indicated for the treatment of Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Non-Small Cell Lung Cancer; Colorectal Cancer; Hepatocellular Carcinoma.
Pro Intelligence Preview
Deep insights for CYRAMZA
Revenue Insights
- • Q4-2025: $200M
- • Historical trend analysis
Patent Timeline
- • Cliff: 2026
- • Generic/biosimilar risk
Trial Analysis
- • 114 total trials
- • Stage: Stable
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment